IRCT20220111053692N1招募中未知
Bioequivalence study of valacyclovir 1000 mg tablet (Avicenna) versus VALTREX ® 1000 mg (GlaxoSmithKline) Tablet in healthy volunteers
Avicenna pharmaceutical Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- Male
入选标准
- •18 to 55 years old
- •Weight in range of 10 % proper body weight
- •All volunteers should be in a good health condition on the basis of medical history ,physical examination , routine blood test.
- •and possessing negative test for hepatitis B surface antigen (HBs-Ag),antihepatitis-C antibody (anti-HCV).and anti-HIV.
排除标准
- •Volunteers with hypersensitivity to valacyclovir were excluded.
- •those with known history of drug abuse. alcohol consumer or cigarette smokers.
- •Taking medications that have drug interactions with valacyclovir until one month before studying.
- •disinclination
- •Blood donation or blood loss of more than 200 ml in the past month
研究者
相似试验
已完成
不适用
Bioequivalence study of valacyclovir 1000 mg tabletBioequivalence study of valacyclovir 1000 mg tablet (Iran Hormone) versus VALTREX ® 1000 mg (GlaxoSmithKline) Tablet in healthy volunteers.IRCT20220111053692N2Iran Hormone pharmaceutical Co.24
招募中
Unknown
Investigating the in vivo bioequivalence of Valacyclovir tabletIRCT20220211053992N9Tabriz University of Medical Sciences24
已完成
1 期
Valacyclovir 1000 mg Tablet Under Fasting ConditionsHealthyNCT01149499Teva Pharmaceuticals USA60
招募中
Unknown
Bioequivalence study of VITALOPHAGE 1000mg tablet of Vitabiotics Pharmed Co., IRAIRCT20190706044111N30Vitabiotix Pharmed24
尚未招募
1 期
Bioequivalence of AbacavirHIV InfectionsPatients seropositive to Human Immunodeficiency Virus (HIV).Human Immunodeficiency VirusVirus DiseasesImmune System DiseasesImmunologic Deficiency SyndromesSexually Transmitted Diseases, ViralRNA Viruses InfectionsRetroviridae InfectionsLentiviruses InfectionsSexually Transmitted DiseasesRPCEC00000252Center for Pharmaceutical Research and Development, Havana, Cuba30